The present invention provides an active cancer vaccine and specifically an immunogenic compositions of membrane vesicles that serve as biomimetic nanoparticles derived from eukaryotic cell membranes that bear N-glycolylneuraminic acid glycoconjugates. These compositions can elicit beneficial immunological responses for treatment of Neu5Gc-positive tumors. The present invention provides methods of generating and using Neu5Gc-conjugated nanoparticles from eukaryotic cells membranes designated nano-ghosts.

The present invention provides an active cancer vaccine and specifically an immunogenic compositions of membrane vesicles that serve as biomimetic nanoparticles derived from eukaryotic cell membranes that bear N-glycolylneuraminic acid glycoconjugates. These compositions can elicit beneficial immunological responses for treatment of Neu5Gc-positive tumors. The present invention provides methods of generating and using Neu5Gc-conjugated nanoparticles from eukaryotic cells membranes designated nano-ghosts.

The present invention features compositions that include a fungal glucosylceramide (GlcCer) purified from a non-pathogenic fungus (e.g., Candida utilis) and, optionally, an adjuvant. The invention also features methods of treating a patient who has a fungal disease and methods of preventing a fungal disease in a subject by administration of these compositions. Also within the scope of the invention are methods of formulating a fungal vaccine by: (a) providing a fungal glucosylceramide isolated from a non-pathogenic fungus; and (b) combining the fungal glucosylceramide with an adjuvant in a physiologically acceptable excipient.

The present invention belongs to the field of biomedicine and relates to use of cannabidiol in the preparation of anti-influenza drugs. Specifically, the present invention relates to use of any one of (1) to (3) below in the preparation of drugs for treating or preventing influenza or drugs for relieving an influenza symptom: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; (2) a plant extract containing cannabidiol; preferably, a cannabis extract containing cannabidiol; preferably, an industrial cannabis extract containing cannabidiol; and (3) a pharmaceutical composition, containing an effective amount of cannabidiol or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable auxiliary materials. The cannabidiol can effectively inhibit influenza viruses, and has the potential to prepare or be used as a drug for treating or preventing influenza.

The present invention belongs to the field of biomedicine and relates to use of cannabidiol in the preparation of anti-influenza drugs. Specifically, the present invention relates to use of any one of (1) to (3) below in the preparation of drugs for treating or preventing influenza or drugs for relieving an influenza symptom: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; (2) a plant extract containing cannabidiol; preferably, a cannabis extract containing cannabidiol; preferably, an industrial cannabis extract containing cannabidiol; and (3) a pharmaceutical composition, containing an effective amount of cannabidiol or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable auxiliary materials. The cannabidiol can effectively inhibit influenza viruses, and has the potential to prepare or be used as a drug for treating or preventing influenza.

The application relates to synthetic composition containing one or more human milk mono- or oligosaccharides which promote mucosal healing in inflammatory GI conditions of humans.

The application relates to synthetic composition containing one or more human milk mono- or oligosaccharides which promote mucosal healing in inflammatory GI conditions of humans.

The application relates to synthetic composition containing one or more human milk mono- or oligosaccharides which promote mucosal healing in inflammatory GI conditions of humans.

A method for treating or preventing a Neisseria gonorrhoeae infection in a subject is provided. The method comprises administering to the subject an effective amount of a compound of general formula I below or a pharmaceutical composition comprising the compound. The compound is a cytidine 5′-monophospho-nonulosonate (CMP-NulO) analog compound, such as cytidine 5′-monophospho-3,7-dideoxy-7-azido-D-glycero-D-galacto-nonulosonic acid (CMP-KDN7N.sub.3).

##STR00001##

A method for treating or preventing a Neisseria gonorrhoeae infection in a subject is provided. The method comprises administering to the subject an effective amount of a compound of general formula I below or a pharmaceutical composition comprising the compound. The compound is a cytidine 5′-monophospho-nonulosonate (CMP-NulO) analog compound, such as cytidine 5′-monophospho-3,7-dideoxy-7-azido-D-glycero-D-galacto-nonulosonic acid (CMP-KDN7N.sub.3).

##STR00001##